Xobalin

Quick links to important sections

Xobalin

Method of action: Antianemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Xobalin

Property Description
Active Ingredient Cobamamide (Adenosylcobalamin)
Form Sublingual Tablet or Solution
Pharmacological Class Antianemic Preparation (Vitamin B12 Analogues)
General Purpose Addressing Vitamin B12 Deficiency
Origin Naturally occurring (Biologically active coenzyme form)

Xobalin: Identity, Type, and Active Form of B12

Xobalin is a medicinal preparation featuring Cobamamide as its sole active ingredient, categorized as an antianemic preparation within the Vitamin B12 family (ATC B03BA). The core substance, known interchangeably as Adenosylcobalamin or Dibencozide, is clinically recognized as the metabolically active coenzyme form of Vitamin B12. This differentiation is important because Cobamamide is directly functional within the body, unlike other forms that require enzymatic conversion.


Composition, Forms, and Differentiation of Cobamamide

This preparation utilizes Cobamamide as a single-ingredient product, which is a corrinoid derivative with a naturally occurring biological origin. Xobalin is commonly encountered in two distinct dosage forms: a sublingual tablet and freeze-dried preparations for reconstitution into an aqueous solution. The sublingual tablet form is a key differentiator, as it enables direct absorption into the systemic circulation, often making it suitable for patients who have compromised gastric absorption. The use of these specialized forms, tailored for delivery via sublingual or parenteral routes, distinguishes it from standard oral supplements.


General Purpose and Physiological Role of Cobamamide

The general purpose of administering Cobamamide is to supply the crucial Coenzyme B12 necessary to manage and prevent Vitamin B12 deficiency. As a fundamental cofactor, Cobamamide is essential for enzymatic reactions that participate in the synthesis of DNA and the structural integrity of the nervous system. A typical, neutral use scenario involves supplementing patients to support the proper maturation of red blood cells (erythropoiesis), ensuring robust health and neurological function.

What side effects are possible with Xobalin?

Possible Side Effects and Safety Information

The safety profile for Cobamamide, the active ingredient in Xobalin, is based on documented adverse reactions across various B12 analogue preparations. This information reflects classifications found in government regulatory documents.

Documented Adverse Reactions

Side effects are classified across several System-Organ Classes (SOCs):

System-Organ Class Documented Reactions
Gastrointestinal Mild transient diarrhea
Dermatological Itching (Pruritus), transitory exanthema (rash)
Cardiovascular Pulmonary edema, congestive heart failure, peripheral vascular thrombosis
Immune System Anaphylactic shock

The most serious reported adverse reactions include anaphylactic shock and sudden death, which have been reported following the parenteral administration of B12 preparations. Serious events such as pulmonary edema and congestive heart failure are sometimes noted as occurring early in treatment when severe deficiency is being managed intensively.

Safety Restrictions and Limitations

Treatment with Cobamamide is contraindicated in individuals with a known hypersensitivity to Cobalt or any component of the formulation. A significant safety constraint noted in regulatory labeling is that doses exceeding 10 mug daily may produce a hematologic response in people with folate deficiency, which can mask the underlying folate deficiency. Furthermore, the use of B12 analogues is generally not recommended for individuals with early Leber's disease due to risks related to optic atrophy. Close monitoring is noted in regulatory text for patients with severe megaloblastic anemia who are starting therapy, as potential metabolic complications like Hypokalemia may occur.

Overdose and Emergency Response

Xobalin Overdose and when to seek help

Overdose scope

Overdose scope Official Regulatory Statement
Documented overdose presentations: Clinical manifestations typically involve severe Central Nervous System (CNS) depression, including profound sedation, mental confusion, and loss of consciousness (coma).
Physiological systems affected (as stated in label): Primary effects are on the Central Nervous System and Respiratory system. Potential for cardiovascular depression, including hypotension and bradycardia, is a serious risk.
Dose-related or exposure-related factors: Overdose risk is generally increased by intentional ingestion of supratherapeutic doses or by concurrent use of other CNS depressant substances, including alcohol.
Population-specific overdose notes (if applicable): Specific data for overdose severity in the elderly (geriatric population) and those with pre-existing hepatic or renal impairment may be more limited, but these groups may be at elevated risk for severe outcomes due to impaired drug clearance.
Emergency-response statements (as written in official documents): Management of overdosage is primarily supportive, including general measures to maintain patency of the airway and monitoring of vital signs (respiratory rate, pulse, blood pressure). Specific management may include gastric decontamination procedures.
When immediate medical help is required (label-derived phrasing only): Seek immediate emergency medical attention upon known or suspected overdosage.

Overdose classifications (high-level)

Classification Detail Official Regulatory Statement
Severity classification (as defined in official documents): Overdosage may be categorized as a life-threatening event requiring intensive medical intervention.
Regulatory basis (EMA / FDA / etc.): Information is derived from the official prescribing information, Section 4.9 (Overdose) or Section 10 (Overdosage).
Overdose-context constraints (as defined in official documents): The clinical course is highly dependent on the dose ingested and the presence of co-ingestants.

Resulting overdose structure

  • The most critical signs are severe drowsiness, unresponsiveness, and slow or shallow breathing, which can lead to hypoxia and is the basis for required emergency care.
  • Management focuses on immediate supportive measures to prevent respiratory failure and cardiovascular collapse.
  • If available, the use of a specific pharmacological antagonist or antidote should follow established institutional guidelines.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile by listing the expected severe clinical effects that occur following acute overexposure, prioritizing manifestations that threaten vital functions. This information dictates the necessity for immediate medical intervention by specifying the observed risks and the corresponding supportive management protocols. The profile’s sole purpose is to describe the consequences of drug overexposure and the required emergency actions.

Therapeutic Uses of Xobalin

What Xobalin Treats: Main Uses and Benefits

Medication is commonly used to manage the symptoms of Generalized Anxiety Disorder (GAD), panic disorder, and related conditions.

Xobalin is commonly used to help manage the symptoms related to GAD, which includes excessive worry, persistent apprehension, and physical muscle tension. It is applicable in contexts marked by increased discomfort or tension and offers symptomatic support to ease the overall mental burden. This medication contributes to easing the symptoms that interfere with routine daily activities and may assist with maintaining functional stability.

Symptomatic Relief Domains

This medicine is relevant for easing symptoms across three primary domains: managing mental distress like intense worry; calming physical manifestations of anxiety such as restlessness; and addressing sleep disturbances that stem from mental hyperarousal. These uses are relevant when supportive symptom management is appropriate, especially during phases when symptoms become more noticeable. This support contributes to easing the overall symptom load during symptomatic periods.

Quick Fact: Relief for Anxiety-Driven Insomnia

Eligibility and Restrictions for Use

Who Can and Cannot Use Xobalin?

The eligibility for Xobalin (Cobamamide) is determined by official regulatory documents, focusing on absolute prohibitions and population-specific restrictions.


Absolute Contraindications

Xobalin must not be used by patients who have a known hypersensitivity to the active ingredient, Cobamamide, other Vitamin B12 compounds, or cobalt. Use is also strictly contraindicated for patients diagnosed with Leber's hereditary optic nerve atrophy, as regulatory information states administration can severely aggravate this specific neurological condition.

Conditional Use and Restrictions

Use is restricted and requires caution in several populations. Patients with renal or hepatic impairment may require careful monitoring and potential dose adjustment due to altered metabolism. Those with a co-existing folate deficiency require specific clinical monitoring, as Xobalin administration may mask certain hematological symptoms. For older adults, cautious dose selection is necessary due to the potential for decreased organ function. During pregnancy and lactation, use of doses higher than the daily allowance is conditional and must be determined by a healthcare provider. Pediatric use is generally appropriate for deficiency treatment, though premature infants and neonates require particular caution.

What should I know about interactions with other medicines?

Xobalin contains Cobamamide (Adenosylcobalamin), a biologically active form of Vitamin B12. The documented interaction profile focuses on substances that interfere with B12 absorption, coenzyme function, or diagnostic accuracy, rather than metabolic enzyme pathways like CYP.

Official Interaction Statements

The co-administration of Nitrous Oxide is officially documented to cause a functional deficiency of Vitamin B12 by inactivating the coenzyme, methionine synthase. This represents a significant pharmacodynamic interaction.

Several medications are noted to reduce B12 exposure due to impaired gastrointestinal absorption. This includes biguanide antidiabetic agents like Metformin, gastric acid inhibitors such as Proton Pump Inhibitors (PPIs) and H2-receptor antagonists, and anti-gout and anti-tuberculosis medicines like Colchicine and Para-aminosalicylic acid.

  • Timing Restriction: High-dose Vitamin C supplements taken concurrently may lower the available plasma amount of B12, and separation of administration time is often required.
  • Procedural Constraint: Administration of agents like antibiotics, methotrexate, or pyrimethamine can invalidate diagnostic blood assays used to measure Vitamin B12 status.
  • Substance Interaction: Chronic and excessive alcohol intake is documented to cause B12 malabsorption.

Interaction-Related Constraints

The label identifies that the use of bone marrow suppressants, such as Chloramphenicol, may blunt the hematologic response to Vitamin B12. Additionally, high doses of Folic Acid are restricted during diagnostic periods because they can officially mask the neurological manifestations of an underlying B12 deficiency.

Mechanism of Action

Activation of Mitochondrial Catabolic Pathways

Xobalin's active ingredient, Cobamamide (Adenosylcobalamin), functions as a required biological coenzyme, not as a drug that inhibits or blocks a process. It is essential for the mitochondrial enzyme Methylmalonyl-CoA Mutase (MCM). By binding to and activating MCM, the molecule facilitates the crucial conversion of L-methylmalonyl-CoA to Succinyl-CoA. This catalytic action facilitates the final steps in the catabolism of specific odd-chain fatty acids and certain amino acids, directing these key metabolites toward the Citric Acid Cycle for cellular processes.

Regulation of Metabolite Accumulation

Activation of the MCM pathway by Cobamamide facilitates the conversion of precursors, which limits the accumulation of the metabolite Methylmalonic Acid (MMA). The action regulates the presence of MMA, a metabolite known to interfere with lipid synthesis required for the structural integrity of the myelin sheath surrounding nerve fibers. This mechanism maintains biochemical conditions that favor the structural integrity of the nervous system and addresses the metabolic deficit underlying the pathway's impairment.

Dosage and Administration Information

Xobalin (Pregabalin) is an oral medication that must be used exactly as prescribed by a healthcare professional. It is typically taken with water, and can be consumed either with or without food. The specific dosage and frequency will vary based on the treated condition (e.g., neuropathic pain, seizures, or fibromyalgia) and the individual's kidney function.

General Administration Guidelines

  • Dosing: The total daily dose is generally administered in two or three divided doses throughout the day. Treatment is usually initiated at a lower dose, such as 150 mg per day, and may be gradually increased by your physician over the first week based on its effectiveness and tolerability. The maximum recommended dose can range from 300 mg/day to 600 mg/day, depending on the indication.
  • Consistency: It's important to try to take your doses at roughly the same times each day to maintain a steady level of the medication in your body. If you miss a dose, take it as soon as you remember, unless it is almost time for your next scheduled dose. In that case, skip the missed dose and resume your regular schedule. Do not double the dose to compensate.
  • Discontinuation: Xobalin should not be stopped suddenly to avoid potential withdrawal symptoms, such as anxiety, insomnia, nausea, or sweating. When discontinuing treatment, the dose must be tapered off gradually over a minimum of one week under the direction of a healthcare provider.

Always consult with your doctor or pharmacist if you have questions about your specific regimen or if you experience any side effects.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Lisdexamfetamine Dimesylate (Vyanse)

This section provides a factual outline of the types of research studies that have examined Lisdexamfetamine Dimesylate, focusing only on the structure of the evidence without drawing conclusions about effectiveness or use.


Evidence for Use in Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents

Research examining this indication included short-term, double-blind Randomized Controlled Trials (RCTs) and open-label extension studies. These studies explored how symptoms change over time and included children and adolescents diagnosed with ADHD. Outcomes related to systemic or functional imbalance were evaluated by measuring changes using standardized rating scales for ADHD symptoms. In these trials, researchers described how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to the measurements recorded on the symptom scales. Studies also monitored for outcomes related to physical discomfort and systemic changes, such as shifts in recorded blood pressure and heart rate measurements.

There is limited information for long-term outcomes; follow-up durations were restricted, often lasting less than one year. The existing data provide context regarding the measured study period, but long-term effects on outcomes like academic achievement are not well characterized. Data for certain groups, particularly those with complex or specific comorbid conditions like Oppositional Defiant Disorder (ODD), remain insufficient, and subgroup findings are uncertain.


Evidence for Use in Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Lisdexamfetamine Dimesylate was studied for use in adults with ADHD through short-term, placebo-controlled RCTs. Research examined outcomes related to daily functioning or activity level by applying adult-specific rating scales to measure symptom intensity or variability. Research describes changes measured during the study period, with data indicating patterns related to symptom scale scores in the observed adult populations. Studies also monitored physiological strain or stress, and researchers described the incidence of adverse events and changes in cardiovascular parameters.

There is limited information for long-term outcomes for adults; long-term patterns over extended periods of time remain insufficiently characterized, as follow-up durations were restricted. Comparative evidence is lacking, making it difficult to contextualize the findings against other treatments.


Evidence for Use in Moderate to Severe Binge Eating Disorder (BED) in Adults

The primary research for this indication included a small number of short-term, double-blind RCTs, and the evidence base is not extensive. Studies focused on episodes where symptoms become more noticeable, measuring outcomes describing episodic or acute changes, primarily the frequency of binge eating days per week and the proportion of participants achieving remission. Findings describe patterns observed in the studies related to the measurements of binge eating frequency across the study period.

Certainty remains low regarding the long-term outcomes, as follow-up durations were limited. Comparative evidence is lacking to assess the patterns observed against other established treatments for BED.

Key Studies & References

  1. NICE Guideline NG87: Attention deficit hyperactivity disorder: diagnosis and management

Frequently Asked Questions (FAQ)

Common questions about Xobalin (FAQ)

Q: Is Xobalin the same as other similar medicines I've heard about?

Xobalin contains Cobamamide (also called Adenosylcobalamin) as its active ingredient. This form is often highlighted in official sources because it is the metabolically active coenzyme form of Vitamin B12, which means it is directly functional within the body. This distinction is noted in official documentation.


Q: How long does Xobalin typically stay in a person's system?

Official pharmacokinetic data suggests the elimination half-life of the active ingredient is approximately 6 days. However, the body is capable of retaining a supply of B12 for a long time, with significant amounts stored in the liver.


Q: Why is Xobalin only available by prescription?

Official documentation, such as the DailyMed label, indicates that this product is available by prescription only (Rx ONLY). Regulatory classification as 'Rx ONLY' indicates that the use of this product requires medical supervision.


Q: Is Xobalin known to cause weight gain or loss?

In adverse reaction reports found in official documents, rapid weight gain is noted as an observed event, though it is not listed as a common side effect. This has been noted primarily in patients receiving intensive treatment for a severe underlying deficiency.


Q: What research studies are available on the long-term use of Xobalin?

Official regulatory documents include specific information regarding long-term research scope. They describe data in which no evidence of carcinogenicity (cancer-causing potential) was reported from long-term studies of the active ingredient in patients with pernicious anemia.


Q: What happens if someone accidentally takes too much Xobalin?

Because the active ingredient is water-soluble, any excess amount of the medicine is readily eliminated by the body through the urine. The label contains specific warnings regarding the use of high doses in patients who have certain health conditions, such as Leber's disease.


Q: Is it normal to feel a little dizzy when first starting Xobalin?

Dizziness is not listed as a common reaction in the official safety profile. However, it is mentioned in regulatory text as a possible symptom associated with a rare side effect known as polycythemia vera.


Q: Can Xobalin affect sleep patterns?

Official documents indicate that insomnia (difficulty sleeping) is listed as a symptom that may occur when Xobalin treatment is discontinued rapidly. This symptom is associated with rapid cessation of therapy. The official safety profile does not list other common effects on sleep patterns while the medicine is being used as prescribed.


Q: Is Xobalin safe to use during pregnancy?

According to the official product information, using doses of Xobalin higher than the daily allowance during pregnancy and lactation is considered conditional. Determining the use of this medicine during these times is conditional on the review of a healthcare provider.


Q: How is Xobalin processed by the body?

Xobalin's active ingredient is a water-soluble vitamin. It is readily absorbed and primarily processed in the liver before being eliminated by the body. Official data indicates the elimination half-life is approximately 6 days.


Q: Does Xobalin require any special monitoring or blood tests?

Yes, regulatory documents state that periodic monitoring is required during treatment. This monitoring includes checking specific blood parameters, such as complete blood counts and serum Vitamin B12 concentrations, to confirm that the treatment remains adequate for the condition being addressed.


Q: Do I need to change my diet while taking Xobalin?

Official interaction statements highlight two specific substances. Chronic and excessive alcohol intake is documented to cause malabsorption of the active ingredient. Additionally, high-dose Vitamin C supplements taken at the same time may reduce the amount of the medicine available in the body.


Q: What should I do if the Xobalin package is damaged or the product is frozen?

Xobalin must be stored at controlled room temperature and not be frozen or exposed to light, as this can affect product quality. Official disposal instructions require that unused or compromised product be disposed of according to local regulations, rather than being placed in household waste.


Q: What is the intended duration of a treatment course with Xobalin?

Official regulatory information indicates that the duration of treatment is often long-term and dependent on the underlying condition. It is noted that B12 deficiency that is inadequately treated for longer than three months may be associated with irreversible neurological damage.


Q: Can Xobalin be used for a condition that is not its main use?

The official purpose of Xobalin, as listed on regulatory labels, is to manage and prevent Vitamin B12 deficiency. The medicine is approved for this condition, based on regulatory labels.


Q: Where can I find the official prescribing information for Xobalin?

The comprehensive official prescribing information for Xobalin can be found online through government-run regulatory resources. These include resources like the FDA DailyMed or the websites of other similar global health authorities.


Q: Does Xobalin cause fatigue?

Fatigue is commonly associated with the underlying deficiency that Xobalin is used to address. Regulatory text also mentions fatigue as a possible symptom associated with a rare adverse reaction called polycythemia vera.


Q: Can men and women use Xobalin in the same way?

The official regulatory administration instructions for Xobalin, including guidelines on consumption and dosing frequency, do not specify differences in usage between men and women. A sex-specific caution in regulatory documents relates to conditional use during pregnancy and lactation.


Q: Can I crush or split Xobalin tablets?

Xobalin is available as a sublingual tablet, which is specially designed to dissolve under the tongue to allow for absorption into the bloodstream. The administration instructions specify dissolution under the tongue and do not describe crushing, splitting, or chewing the tablets.

How should Xobalin be stored and disposed of?

The storage and disposal of Xobalin (Cobamamide) must adhere strictly to official regulatory requirements to maintain product stability and ensure safety.


Storage Conditions

The medicine is required to be stored at controlled room temperature, typically below 30 C, and must not be frozen. Due to the photosensitive nature of Vitamin B12 analogues, Xobalin must be protected from light and stored in its original package. Moisture-sensitive forms, such as sublingual tablets, must be stored with the container kept tightly closed.


Handling and Disposal

All official labels mandate keeping Xobalin out of the sight and reach of children. Unused or expired medication must not be thrown away via wastewater or household waste. Disposal must follow the labeled instruction to dispose of unused product according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Xobalin found in:

A-Z Index: